Nexalin Technology, Inc. announced on December 23, 2024, the completion of Phase 1 of its proprietary virtual clinic. This innovative platform integrates artificial intelligence (AI) with a new Electronic Data Capture (EDC) platform and Patient Monitoring System (PMS).
The AI ecosystem is designed to facilitate the entire clinical trial process and future treatment experiences virtually, allowing patients to receive care in their homes. It also provides physicians with real-time digital data related to patient treatment.
This virtual clinic is specifically designed to manage clinical research and streamline the patient experience for Nexalin’s Generation 3 Halo Device, which administers 15mAmp deep frequency stimulation. The system ensures compliance with study protocols and enables remote monitoring and personalized care through an interactive smartphone application and telemedicine features.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.